Dynavax Technologies (NASDAQ:DVAX) Rating Lowered to Sell at The Goldman Sachs Group

Dynavax Technologies (NASDAQ:DVAX - Get Free Report) was downgraded by investment analysts at The Goldman Sachs Group from a "neutral" rating to a "sell" rating in a research report issued to clients and investors on Tuesday, Marketbeat Ratings reports. They presently have a $12.00 price objective on the biopharmaceutical company's stock, down from their previous price objective of $15.00. The Goldman Sachs Group's target price would suggest a potential downside of 6.51% from the company's previous close.

Several other research firms also recently commented on DVAX. StockNews.com raised shares of Dynavax Technologies from a "hold" rating to a "buy" rating in a research note on Tuesday, January 14th. HC Wainwright raised their price target on shares of Dynavax Technologies from $29.00 to $31.00 and gave the stock a "buy" rating in a research note on Tuesday, January 14th.

Dynavax Technologies Trading Up 1.1 %

Shares of Dynavax Technologies stock traded up $0.15 during trading on Tuesday, hitting $12.84. The stock had a trading volume of 428,254 shares, compared to its average volume of 1,756,369. The firm's fifty day simple moving average is $12.80 and its 200-day simple moving average is $11.92. The stock has a market cap of $1.69 billion, a PE ratio of 98.99 and a beta of 1.32. The company has a debt-to-equity ratio of 0.33, a current ratio of 13.23 and a quick ratio of 12.34. Dynavax Technologies has a 12 month low of $9.74 and a 12 month high of $13.89.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in DVAX. Assenagon Asset Management S.A. purchased a new position in Dynavax Technologies during the 3rd quarter valued at about $8,291,000. Norges Bank purchased a new position in Dynavax Technologies during the 4th quarter valued at about $7,762,000. PDT Partners LLC purchased a new position in Dynavax Technologies during the 3rd quarter valued at about $3,967,000. WINTON GROUP Ltd increased its position in Dynavax Technologies by 339.0% during the 4th quarter. WINTON GROUP Ltd now owns 426,814 shares of the biopharmaceutical company's stock valued at $5,450,000 after purchasing an additional 329,579 shares during the period. Finally, Trexquant Investment LP increased its position in Dynavax Technologies by 48.7% during the 4th quarter. Trexquant Investment LP now owns 776,397 shares of the biopharmaceutical company's stock valued at $9,915,000 after purchasing an additional 254,405 shares during the period. Hedge funds and other institutional investors own 96.96% of the company's stock.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.